1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Vivesto AB

Vivesto AB

SSTO:VIVE
7.22
SEK
+0.40
(+5.87%)
-3.99EPS
94.11MMarket Cap
Nov 12Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.04
1.23
3.59
0.08
1.09
0.59
44.1
5.08
0.18
- -
- -
- -
- -
Basic EPS, GAAP
-56.85
-69.02
-69.74
-79.75
-77.15
-40.71
-59.69
-2.3
-25.76
-62.93
-20.83
-6.43
-5.51
-3.99
Free Cash Flow per Basic Share
-104.91
-80.49
-76.39
-83.43
-67.87
-50.05
-38.8
-4.31
-34.92
-15.18
-11.23
-7.64
-8.68
-3.11
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
210.3
177.51
208.87
165.45
129.59
112.14
97.77
159.06
106.71
52.76
32
25.61
20.15
14.29
Tangible Book Value per Share
-25.07
-67.88
-16.3
-48.6
-65.89
-41.28
-15.33
73.04
21.22
21.65
9.33
3.74
-3.02
1.4
Basic Weighted Avg Shares
1
2
2
2
2
3
3
5
5
6
6
6
6
8
Sales/Revenue/Turnover
- -
- -
2
6
- -
3
2
202
26
1
- -
- -
- -
- -
Operating Margin (%)
- -
-170,568.33
-5,234.98
-2,082.11
-81,792.44
-3,278.04
-7,613.59
-15.07
-502.14
-35,243.55
- -
- -
- -
- -
Depreciation Expense
5
5
5
5
5
5
31
20
29
252
57
3
2
1
Net Income, GAAP
-72
-105
-117
-142
-160
-118
-201
-11
-133
-357
-129
-40
-34
-32
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-175,186.67
-5,676.18
-2,220.92
-93,164.53
-3,723.79
-10,166.92
-5.22
-506.73
-35,134.19
- -
- -
- -
- -
Working Capital
-63
-131
-52
-117
-171
-143
-44
355
97
129
57
23
-19
15
LT Debt
- -
- -
- -
- -
- -
- -
- -
9
5
5
- -
- -
- -
- -
Total Equity
319
282
376
326
300
345
383
819
550
326
198
158
125
158
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-24.43
-34.98
-35.73
-40.34
-51.16
-36.57
-55.26
-1.75
-19.39
-81.43
-49.14
-22.33
-24.09
-21.1

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
13
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
11
11
Market Capitalization
73
89
94

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5
35
25
Cash, Cash Equivalents & STI
2
31
24
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
24
11
10
Payables & Accruals
- -
- -
- -
ST Debt
13
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.56%
-30.84%
-21.32%
Free Cash Flow
64.01%
144.32%
13.58%
Net Income, GAAP
116.46%
236.29%
-14.27%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.36
-1.68
-1.66
-1.73
-6.43
2025
-1.34
-1.77
-1.16
-1.47
-5.51
2026
-0.84
-0.76
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Erik Kinnman
Full Time Employees
4
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
Gustav III:s Boulevard 46 Solna Sweden 169 73
IPO Date
Jun 24, 2010
Website
vivesto.com
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
Vivesto AB (VIVE.ST), a Swedish pharmaceutical company headquartered in Solna, develops and commercializes oncology drugs utilizing proprietary XR-17 technology platform to create water-soluble micellar formulations that enhance drug efficacy and safety profiles. Founded in 1988 and formerly known as Oasmia Pharmaceutical AB until its rebranding in March 2022, the company focuses on hard-to-treat cancers in humans and veterinary applications; its core pipeline includes Apealea (paclitaxel micellar), a marketed treatment for platinum-resistant ovarian cancer commercialized through partnerships such as with Elevar Therapeutics; Cantrixil (TRX-E-002-1), a tubulin inhibitor in preclinical development for hematological cancers including blood malignancies; Docetaxel micellar, in clinical stages for advanced prostate cancer; and Paccal Vet (paclitaxel micellar), a veterinary oncology product under evaluation in pilot clinical trials for dogs with splenic hemangiosarcoma post-splenectomy and in dose-finding studies for cats with solid tumors; the company also maintains Doxophos Vet (doxorubicin formulation) for canine lymphoma in its animal health portfolio. Vivesto operates primarily in Europe with global commercialization ambitions through strategic alliances and targets patients with advanced cancers alongside veterinary markets. Recent developments include the March 2025 acquisition of full global rights to Cantrixil from Kazia Therapeutics for USD 1 million following positive preclinical data in hematological cancers, supporting accelerated manufacturing for clinical trials and new IP filings; in November 2025, the company announced a fully secured rights issue of approximately SEK 53.8 million to fund Paccal Vet and Cantrixil advancement toward partnerships anticipated in 2026-2027; positive interim progress in Paccal Vet trials and Q3 2025 financial reporting underscore ongoing pipeline momentum.